Pioneering Novel
Small Molecule Therapeutics
to address diseases driven by intestinal microbial-driven inflammation

Artizan Biosciences is at the frontier of microbiome precision medicine, targeting, and blocking intestinal microbial-driven inflammation that are the root cause of many serious diseases.

Broad Approach

Using a novel small molecule approach, Artizan modulates intestinal dysbiosis by inhibiting specific, disease-associated microbial virulence factors in the intestinal tract.

Read More

Discovery Platform

Artizan’s proprietary drug discovery engine identifies and characterizes microbial drivers of disease within precise patient subsets in high-value areas including gastrointestinal, metabolic, autoimmune, and neurodegenerative diseases.

Read More

News

Artizan’s world-class biobanking program collects proprietary samples and clinical data from patients and healthy controls. These samples enable critical research into disease mechanisms and aid the development of potential treatments.